3-(4-(4,6-dipropyl-1,1-bis(trifluoromethyl)-1,3-dihydroisobenzofuran-5-yloxy)butyl)-5-(4-ethylphenyl)-5-methylimidazolidine-2,4-dione | 1189172-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(4-(4,6-dipropyl-1,1-bis(trifluoromethyl)-1,3-dihydroisobenzofuran-5-yloxy)butyl)-5-(4-ethylphenyl)-5-methylimidazolidine-2,4-dione
• 英文别名: 3-[4-[[4,6-dipropyl-1,1-bis(trifluoromethyl)-3H-2-benzofuran-5-yl]oxy]butyl]-5-(4-ethylphenyl)-5-methylimidazolidine-2,4-dione
• CAS: 1189172-87-9
• 化学式: C₃₂H₃₈F₆N₂O₄
• 分子量: 628.655
• InChiKey: MNESFUFUHZXXGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  44
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• 1,3-DIHYDROISOBENZOFURAN DERIVATIVES
  申请人：OKUDA Ayumu

  公开号：US20090247587A1

  公开（公告）日：2009-10-01

  The object is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. The solving means is a 1,3-dihydroisobenzofuran derivative represented by the following general formula (1) or salt thereof, or their solvate.

  该目的是提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；皮肤疾病，如过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。解决方法是由以下一般式（1）表示的1,3-二氢异苯并呋喃衍生物或其盐，或它们的溶剂化合物。
• 1,3-DIHYDROISOBENZOFURAN DERIVATIVE
  申请人：Kowa Company, Ltd.

  公开号：EP2264029A1

  公开（公告）日：2010-12-22

  The object is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. The solving means is a 1,3-dihydroisobenzofuran derivative represented by the following general formula (1) or salt thereof, or their solvate.

  本发明的目的是提供一种新型 LXRβ 激动剂，它可作为动脉粥样硬化、动脉硬化（如糖尿病引起的动脉硬化）、血脂异常、高胆固醇血症、血脂相关疾病、由炎症细胞因子引起的炎症性疾病、皮肤病（如过敏性皮肤病）、糖尿病或阿尔茨海默病的预防和/或治疗药物。溶解手段是由以下通式（1）代表的 1，3-二氢异苯并呋喃衍生物或其盐，或它们的溶解物。
• US7951822B2
  申请人：——

  公开号：US7951822B2

  公开（公告）日：2011-05-31